Vancomycin: Discovery, Structure, and Mode of Action

Discovery and Historical Development of Vancomycin

  • Needed new antibiotics capable of treating infections caused by penicillin-resistant strains

  • Compound was deemed too impure

History and Clinical Status Evolution

  • Removal from First-Line Treatment: Shortly after its introduction, Vancomycin fell out of favor as a first-line treatment due to three primary factors:

    1. Poor bioavailability.

    2. The development of semi-synthetic penicillins (e.g., methicillin).

    3. Its reputation as "Mississippi Mud" due to its impurity profile.

  • Modern Resurgence: In recent years, Vancomycin has seen a resurgence in clinical use primarily due to the emergence of nosocomial (hospital-acquired) methicillin-resistant Staphylococcus aureus (MRSA) infections.

Chemical Structure and Properties

  • General Classification: Vancomycin is a branched tricyclic glycosylated peptide.

  • Molecular Characteristics:

    • It is a large, hydrophilic molecule.

    • It is structurally unique and unrelated to any other category of antibiotic.

    • It contains a heptapeptide (7-amino acid) backbone.

  • Glucosylation: The molecule features a disaccharide unit consisting of:

    • Glucose

    • Vancosamine

Spectrum of Activity and Physiology

  • Classification: Bactericidal glycopeptide antibiotic.

  • Spectrum: Narrow spectrum.

    • Effective only against Gram-positive bacteria (e.g., Streptococci, Enterococci, and Staphylococci).

    • Ineffective against Gram-negative bacteria because the lipopolysaccharide layer of the complex gram-negative cell wall acts as an impenetrable barrier to the large Vancomycin molecule.

  • Active State Requirement: Vancomycin only works against actively dividing bacterial cells.

The "Triple Threat" Mechanism of Action

Vancomycin utilizes three distinct actions to achieve its bactericidal effect:

  1. Cell Wall Synthesis Inhibition: The primary mechanism; it prevents the construction of the peptidoglycan layer.

  2. Bacterial-Cell-Membrane Permeability: It increases the permeability of the membrane, leading to leakage of cellular components.

  3. RNA Synthesis Inhibition: It interferes with the production of bacterial RNA.

Specific Molecular Mode of Action: Peptidoglycan Inhibition

  • Normal Peptidoglycan Synthesis Steps:

    1. Formation of NAM (N-acetylmuramic acid) and NAG (N-acetylglucosamine) pentapeptide.

    2. Transport of these building blocks into the periplasm via a lipid carrier (Lipid II).

    3. Insertion into the peptidoglycan polymer by transglycosylases.

    4. Formation of peptide cross-links between NAM monomers by transpeptidases to provide cell wall strength.

  • Vancomycin Intervention:

    • Vancomycin binds to the two terminal D-alanine (D-Ala-D-Ala) residues of the NAM pentapeptide at the C-terminal of Lipid II.

    • This binding creates steric hindrance.

    • Consequences:

      • Blocks the formation of glycosidic bonds between the sugars (transglycosylation).

      • Blocks the formation of peptide cross-links (transpeptidation).

      • Prevents the recycling of the lipid carrier, thus stopping new monomers from crossing the lipid bilayer.

    • Outcome: The weakened cell wall cannot withstand the high internal osmotic pressure of the bacterium, leading to cell lysis (bactericidal action).

Molecular Binding and Selective Toxicity

  • Binding Geometry: Vancomycin has a cup-shaped pocket (concave surface). The D-Ala-D-Ala peptide tail fits into this pocket. It aligns in the opposite direction to the vancomycin backbone.

  • Hydrogen Bonding: The Vancomycin molecule forms exactly 55 hydrogen bonds with the D-Ala-D-Ala dipeptide within a carboxylate binding pocket.

    • This is important because if the drug binds tightly enough, enzymes cannot access the peptide, peptidoglycan cross-linking stops, the cell wall weakens and the bacterium dies.

  • Hydrophobic Shielding: The N-methyl-leucine residue (position 1) folds in to form the binding pocket, providing hydrophobic shielding. This hydrophobic region acts like a protective cover, making the binding stronger and more stable.

  • Dimerization:

    • Two vancoycin molecules can align back-to-back to form a dimer.

    • Dimerization involves 44 hydrogen bonds between two anti-parallel polypeptide backbones.

    • The disaccharides interact over a large hydrophobic surface, creating two substrate binding pockets.

    • Co-operativity of Binding: When one vancomycin molecule in the dimer binds a D-Ala-D-Ala target, the second molecule is automatically positioned near another nearby target. This increases the likelihood of the second binding event as it increases overall affinity for the dimer. This is called cooperative binding.

  • Selective Toxicity Principles: Vancomycin causes harm to bacteria but not the host (humans). This is because it targets peptidoglycan, which is absent in human cells. Furthermore, the D-alanine residues targeted by Vancomycin are not found in human proteins.

Pharmacokinetics and Administration

  • Oral Administration:

    • Vancomycin is very poorly absorbed in the gastrointestinal tract.

    • It is used orally only for localized infections within the gut, such as Clostridioides difficile (pseudomembranous colitis).

  • Intravenous (IV) Administration:

    • Used for severe, systemic infections (e.g., MRSA).

    • Typically a "last resort" antibiotic for patients allergic to penicillin or those with methicillin-resistant infections.

Therapeutic Monitoring and Clinical Cautions

  • Contraindications and Cautions:

    • Renal Function: Not to be used in patients with impaired renal function without extreme caution and monitoring.

    • Drug Interactions: Conflicts with many commonly used drugs, such as Non-Steroidal Anti-Inflammatory Drugs (NSAIDs).

    • Demographics: Use with extreme caution in children and the elderly.

    • Tissue Irritation: The drug is intensely irritating to tissues.

Adverse Effects

  • Vancomycin Infusion Reaction (Red Man Syndrome):

    • Characterized by a red rash on the neck, face, and upper torso.

    • Typically occurs between 55 minutes and 11 hour after starting an infusion.

  • Nephrotoxicity: Potential for kidney damage, particularly when used with other nephrotoxic agents like aminoglycosides.

  • Ototoxicity: Damage to the ear/hearing (less common).

  • Systemic Side Effects: Chills, fever, skin rash.

  • Oral Side Effects: Abdominal pain, nausea, dysgeusia (distorted sense of taste), headache, and fatigue.